Baillie Gifford & Co. decreased its holdings in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 4.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 15,149,203 shares of the biotechnology company's stock after selling 722,672 shares during the period. Baillie Gifford & Co. owned 6.14% of Adaptimmune Therapeutics worth $14,769,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Columbia Advisory Partners LLC purchased a new stake in Adaptimmune Therapeutics during the 1st quarter valued at about $25,000. JTC Employer Solutions Trustee Ltd purchased a new position in Adaptimmune Therapeutics during the first quarter worth about $41,000. Twin Focus Capital Partners LLC purchased a new stake in Adaptimmune Therapeutics in the fourth quarter valued at $44,000. Finally, Boulder Hill Capital Management LP purchased a new position in shares of Adaptimmune Therapeutics during the 1st quarter worth approximately $143,000. Institutional investors own 31.37% of the company's stock.
Adaptimmune Therapeutics Stock Performance
Shares of NASDAQ ADAP traded up $0.04 during trading on Friday, hitting $1.21. The company had a trading volume of 1,060,856 shares, compared to its average volume of 1,824,790. The company has a market cap of $298.66 million, a P/E ratio of -1.64 and a beta of 2.31. The business's 50-day moving average is $1.11 and its 200 day moving average is $1.21. Adaptimmune Therapeutics plc has a 52 week low of $0.42 and a 52 week high of $2.05.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $4.00 price objective on shares of Adaptimmune Therapeutics in a research report on Tuesday, August 13th. Scotiabank assumed coverage on Adaptimmune Therapeutics in a research note on Thursday, May 30th. They set a "sector outperform" rating and a $3.15 price target for the company. StockNews.com raised Adaptimmune Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 13th. Finally, Mizuho reduced their price objective on Adaptimmune Therapeutics from $9.00 to $3.00 and set a "buy" rating for the company in a report on Friday, May 17th.
Get Our Latest Stock Report on ADAP
About Adaptimmune Therapeutics
(
Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Stories
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
